Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.
The extraordinary sensitivity and specificity of T cells for their cognate antigen make them a highly attractive cancer therapeutic. However, the rarity of tumor-reactive T cells in cancer patients, the difficulty isolating them in sufficient numbers for adoptive immunotherapy, and the unpredictable persistence of transferred cells have been significant obstacles to broad application. Technologies that enable genetic modification of T cells have been refined and are being used to redirect the specificity of T cells to tumor antigens. An issue the field is now grappling with is how the diverse phenotypic and functional heterogeneity in T cells that could potentially be genetically modified can be capitalized upon to enhance the efficacy, safety, and reproducibility of cancer immunotherapy.
Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
Cameron J
CJ
Turtle
Stanley R
SR
Riddell
D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D002454:Cell Differentiation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
Nat Med. 2003 Sep;9(9):1131-7
12925846
Blood. 2010 Feb 4;115(5):925-35
19880495
Nat Biotechnol. 2002 Jan;20(1):70-5
11753365
Immunol Rev. 2010 Jul;236:151-66
20636815
Science. 2000 Oct 6;290(5489):92-7
11021806
J Immunol. 2009 Jan 1;182(1):164-70
19109147
J Immunol. 2006 Nov 1;177(9):6548-59
17056587
Curr Opin Immunol. 2009 Apr;21(2):209-14
19321326
Blood. 2010 Nov 25;116(22):4532-41
20702778
J Immunol. 2011 Jan 15;186(2):685-96
21149604
Nat Immunol. 2010 Aug;11(8):701-8
20581831
Nat Med. 2008 Nov;14(11):1264-70
18978797
Blood. 2009 Nov 5;114(19):4099-107
19706884
Nature. 2009 Jul 2;460(7251):108-12
19543266
Mol Ther. 2011 Mar;19(3):620-6
21157437
Immunity. 2007 Sep;27(3):393-405
17892848
Cancer Sci. 2010 Dec;101(12):2518-24
20880333
Cancer Res. 2005 Oct 1;65(19):9080-8
16204083
J Immunol. 2004 Dec 15;173(12):7125-30
15585832
Immunity. 2008 May;28(5):662-74
18424189
Blood. 2005 Nov 1;106(9):3062-7
16020516
Nat Med. 2009 Jul;15(7):808-13
19525962
J Med Primatol. 2011 Apr;40(2):88-103
21044089
Mol Ther. 2010 Apr;18(4):843-51
20179677
Blood. 2011 Jan 20;117(3):808-14
20971955
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3006-11
20133607
Immunity. 2009 Nov 20;31(5):834-44
19879163
J Clin Invest. 2008 Jan;118(1):294-305
18060041
Nat Rev Immunol. 2007 May;7(5):340-52
17438575
Cancer Immunol Immunother. 2009 Mar;58(3):383-94
18677478
Mol Ther. 2010 Oct;18(10):1744-5
20885433
Curr Opin Mol Ther. 2010 Feb;12(1):55-63
20140817
Nat Med. 2010 May;16(5):565-70, 1p following 570
20400962
Nature. 2003 Mar 13;422(6928):164-9
12634786
Nat Med. 2005 Dec;11(12):1299-305
16288282
Nature. 2009 Jul 2;460(7251):103-7
19494812
Mol Ther. 2010 Apr;18(4):666-8
20357779
Biol Blood Marrow Transplant. 1998;4(2):75-83
9763110
Curr Gene Ther. 2008 Dec;8(6):438-48
19075627
Immunity. 2010 Sep 24;33(3):412-23
20850354
N Engl J Med. 1995 Oct 19;333(16):1038-44
7675046
Blood. 2011 Feb 10;117(6):1888-98
21123821
Immunol Rev. 2010 May;235(1):219-33
20536566
Science. 2006 Oct 6;314(5796):126-9
16946036
Blood. 2003 Feb 15;101(4):1637-44
12393484
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74
19805141
J Clin Oncol. 2006 May 1;24(13):e20-2
16648493
J Clin Oncol. 2008 Nov 10;26(32):5233-9
18809613
Mol Ther. 2010 Apr;18(4):674-83
20104209
Immunity. 2007 Dec;27(6):985-97
18082432
Blood. 1990 Feb 1;75(3):555-62
2297567
Nat Rev Immunol. 2002 Jul;2(7):512-9
12094225
Trends Mol Med. 2010 Feb;16(2):77-87
20122868
Immunol Rev. 2010 Jul;236:167-75
20636816
Blood. 2011 Jan 27;117(4):1250-9
21084709